Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 19/20 | 0.62 |
| ▸ | EGFR | P00533 | 16/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | PRKCG | P05129 | 1/20 | 0.60 |
| ▸ | PRKCB | P05771 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.60 |
| ▸ | PRKCA | P17252 | 1/20 | 0.60 |
| ▸ | PRKCH | P24723 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | PRKCI | P41743 | 1/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.60 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.60 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4068149 | 0.91 | ERBB2 (0.73) | ERBB2EGFRPRKD3PRKCGPRKCB | |
| SCHEMBL14208289 | 0.88 | ERBB2 (0.56) | ERBB2EGFRPRKD3PRKCGPRKCB | |
| SCHEMBL5266181 | 0.82 | ERBB2 (0.61) | ERBB2EGFR | |
| SCHEMBL4069343 | 0.82 | ERBB2 (0.61) | ERBB2EGFR | |
| SCHEMBL4064952 | 0.81 | ERBB2 (0.63) | ERBB2EGFRPRKD3PRKCGPRKCB | |
| SCHEMBL3373751 | 0.80 | ERBB2 (0.69) | ERBB2EGFR | |
| SCHEMBL3377629 | 0.80 | ERBB2 (0.71) | ERBB2EGFR | |
| SCHEMBL4066817 | 0.80 | EGFR (0.52) | ERBB2EGFRPRKD3LCKPRKCA | |
| SCHEMBL4068899 | 0.80 | EGFR (0.52) | ERBB2EGFRPRKD3LCKPRKCA | |
| Hydrochloric Acid SCHEMBL4029419 | 0.79 | ERBB2 (0.70) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863792-B1 | ATP COMPETITIVE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-21 | — | — | EP | claimed |
| US-7358256-B2 | ATP competitive kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-15 | — | — | US | claimed |
| EP-1863792-A1 | ATP COMPETITIVE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2007-12-12 | — | — | EP | claimed |
| WO-2006104971-A1 | ATP COMPETITIVE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-05 | — | — | WO | claimed |
| US-20060217369-A1 | Antiproliferative agents; tyrosine kinase inhibitors; anticancer; diseases associated with signal transduction pathways operating through growth factor receptors; 4-amino-1-((4-(3-methoxyphenylamino) quinazolin-5-yl)methyl)-N-methylpiperidine-3-carboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-28 | — | — | US | claimed |
| EP-1863792-B1 | ATP COMPETITIVE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-21 | — | — | EP | disclosed |
| US-7358256-B2 | ATP competitive kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358256-B2 | ATP competitive kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358256-B2 | ATP competitive kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| US-20060217369-A1 | Antiproliferative agents; tyrosine kinase inhibitors; anticancer; diseases associated with signal transduction pathways operating through growth factor receptors; 4-amino-1-((4-(3-methoxyphenylamino) quinazolin-5-yl)methyl)-N-methylpiperidine-3-carboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217369-A1 | Antiproliferative agents; tyrosine kinase inhibitors; anticancer; diseases associated with signal transduction pathways operating through growth factor receptors; 4-amino-1-((4-(3-methoxyphenylamino) quinazolin-5-yl)methyl)-N-methylpiperidine-3-carboxamide | ERBB2, ERBB4, EGFR | ERBB2 1/4885EGFR 3/4885PRKD3 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.